30% off. Use code SUMMERSALE30 at checkout for 30% off for 12 months on Plus, Pro and Premium subscriptions. Subscribe now
United States Biotechnology & Medical Research

Atossa Therapeutics Inc (ATOS)

Track

The most recent insider trading activity occurred on May 21, 2025, with a BUY transaction by Steven C. Quay, President & CEO, for 11,239 shares valued at $9,886.95. Prior to this, on March 26, 2025, H. Lawrence Remmel made a BUY transaction of 10,000 shares for $7,000. These recent BUYs follow a SELL transaction in November 2023.
Stock chart
Ticker: ATOS Exchange: NAS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Top insiders
Trades
QUAY STEVEN C
President & CEO
1 purchase — total 9,887 USD
Buy 21 May 2025
Value US$1,994,577.53 | Price 66.68 | Shares 97,632
Buy 26 Mar 2025
Value US$141,684.23 | Price 97.24 | Shares 69,581
Buy 10 Apr 2024
Value US$44,250.00 | Price 1.77 | Shares 25,000
Sale 15 Nov 2023
Value US$32,500.00 | Price 0.65 | Shares 50,000
Buy 20 Jun 2023
Value US$48,500.00 | Price 0.97 | Shares 50,000
Buy 15 Nov 2017
Value US$471.10 | Price 0.34 | Shares 1,400
Buy 15 Nov 2017
Value US$2,898.20 | Price 0.34 | Shares 8,600
Buy 17 Apr 2017
Value US$1,580.00 | Price 0.63 | Shares 2,500
Buy 1 Apr 2016
Value US$495.00 | Price 0.33 | Shares 1,500
Buy 9 Mar 2016
Value US$5,550.00 | Price 0.37 | Shares 15,000
Buy 9 Mar 2016
Value US$5,550.00 | Price 0.37 | Shares 15,000
Buy 16 Feb 2016
Value US$7,950.00 | Price 0.53 | Shares 15,000
Buy 16 Feb 2016
Value US$7,950.00 | Price 0.53 | Shares 15,000
Buy 19 Jan 2016
Value US$10,000.00 | Price 0.20 | Shares 50,000
Buy 19 Jan 2016
Value US$10,000.00 | Price 0.20 | Shares 50,000
Buy 12 Jun 2015
Value US$7,020.00 | Price 1.30 | Shares 5,400
Buy 15 May 2013
Value US$2,744.95 | Price 5.49 | Shares 500
Buy 8 Jan 2013
Value US$8,100.00 | Price 4.05 | Shares 2,000
Buy 8 Jan 2013
Value US$6,720.00 | Price 4.20 | Shares 1,600
Buy 8 Jan 2013
Value US$1,640.00 | Price 4.10 | Shares 400
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2025-05-22 2025-05-21 B Purchase
1.3
QUAY STEVEN C

President & CEO

Executive Director
97,632 -6.6%
66.68
US$1,994,578 		97,632 -6.6% 66.68 US$1,994,578
2025-03-28 2025-03-26 B Purchase
3.1
Remmel H. Lawrence
Non-Executive Director
69,581 +45.9%
97.24
US$141,684 		69,581 +45.9% 97.24 US$141,684
2024-04-11 2024-04-10 B Purchase
0.6
Finn Jonathan
Non-Executive Director
92,101 +2.9%
456.15
US$4,028,165 		92,101 +2.9% 456.15 US$4,028,165
2023-11-17 2023-11-15 S Sale
1.4
WEAVER GREGORY L

Former EVP, CFO, & Director

Executive Director
50,000 -99.9%
0.65
US$32,500 		50,000 -99.9% 0.65 US$32,500
2023-06-20 2023-06-20 B Purchase
1.4
WEAVER GREGORY L

EVP & CFO

Executive Director
50,000 +90909.1%
0.97
US$48,500 		50,000 +90909.1% 0.97 US$48,500
2017-11-16 2017-11-15 B Purchase
2.5
Guse Kyle

CFO, Gen Counsel and Secretary
1,400 +16.3%
0.34
US$471 		1,400 +16.3% 0.34 US$471
2017-11-16 2017-11-15 B Purchase Guse Kyle

CFO, Gen Counsel and Secretary
8,600 +inf%
0.34
US$2,898 		8,600 +inf% 0.34 US$2,898
2017-04-18 2017-04-17 B Purchase Remmel H. Lawrence
2,500 +399.4%
0.63
US$1,580 		2,500 +399.4% 0.63 US$1,580
2016-04-04 2016-04-01 B Purchase Remmel H. Lawrence Non-Executive Director
1,500 +16.0%
0.33
US$495 		1,500 +16.0% 0.33 US$495
2016-03-10 2016-03-09 B Purchase Chen Shu-Chih Non-Executive Director Large shareholder
15,000 +0.3%
0.37
US$5,550 		15,000 +0.3% 0.37 US$5,550
2016-03-10 2016-03-09 B Purchase QUAY STEVEN C

President & CEO

Executive Director Large shareholder
15,000 +0.3%
0.37
US$5,550 		15,000 +0.3% 0.37 US$5,550
2016-02-17 2016-02-16 B Purchase Chen Shu-Chih Non-Executive Director Large shareholder
15,000 +0.3%
0.53
US$7,950 		15,000 +0.3% 0.53 US$7,950
2016-02-17 2016-02-16 B Purchase QUAY STEVEN C

President & CEO

Executive Director Large shareholder
15,000 +0.3%
0.53
US$7,950 		15,000 +0.3% 0.53 US$7,950
2016-01-21 2016-01-19 B Purchase
3.3
Chen Shu-Chih
Non-Executive Director Large shareholder
50,000 +1.2%
0.20
US$10,000 		50,000 +1.2% 0.20 US$10,000
2016-01-21 2016-01-19 B Purchase QUAY STEVEN C

President & CEO

Executive Director Large shareholder
50,000 +1.1%
0.20
US$10,000 		50,000 +1.1% 0.20 US$10,000
2015-06-15 2015-06-12 B Purchase Remmel H. Lawrence Non-Executive Director
5,400 +135.0%
1.30
US$7,020 		5,400 +135.0% 1.30 US$7,020
2013-06-27 2013-05-15 B Purchase CROSS ALEXANDER D Non-Executive Director
500 +0.6%
5.49
US$2,745 		500 +0.6% 5.49 US$2,745
2013-01-09 2013-01-08 B Purchase Remmel H. Lawrence Non-Executive Director
2,000 +inf%
4.05
US$8,100 		2,000 +inf% 4.05 US$8,100
2013-01-09 2013-01-08 B Purchase
3.3
Remmel H. Lawrence
Non-Executive Director
1,600 +400.0%
4.20
US$6,720 		1,600 +400.0% 4.20 US$6,720
2013-01-09 2013-01-08 B Purchase
3.3
Remmel H. Lawrence
Non-Executive Director
400 +inf%
4.10
US$1,640 		400 +inf% 4.10 US$1,640
Explore more

More insider trading research around Atossa Therapeutics Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America